8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 27, 2026·SEC
Health Catalyst, Inc.(HCAT)Earnings, Financials & Key Ratios
HCAT•NASDAQ
Price updated Jun 19, 2026
AboutHealth Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.Show more
- Revenue$311M+1.5%
- EBITDA$14M+150.7%
- Net Income-$178M-156.1%
- EPS (Diluted)-2.55-121.7%
- Gross Margin33.47%-27.1%
- EBITDA Margin4.63%+150.0%
- Operating Margin-11.6%+49.0%
- Net Margin-57.2%-152.3%
- ROE-58.26%-206.8%
HCAT Key Insights
Health Catalyst, Inc. (HCAT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 10.5%
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 16.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HCAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HCAT Price & Volume
Health Catalyst, Inc. (HCAT) stock price & volume — 10-year historical chart
Loading chart...
HCAT Growth Metrics
Health Catalyst, Inc. (HCAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years10.5%
3 Years4.05%
TTM-2.83%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-265.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-223.48%
Return on Capital
10 Years-31.2%
5 Years-16.57%
3 Years-13.2%
Last Year-7.63%
HCAT Recent Earnings
Health Catalyst, Inc. (HCAT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.02+100.0%
$0.01
Rev
$71M+2.2%
$69M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.08-11.1%
$0.09
Rev
$75M+1.0%
$74M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.06+20.0%
$0.05
Rev
$76M+3.0%
$74M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.04+33.3%
$0.03
Rev
$81M-5.2%
$85M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.02vs $0.01+100.0% | $71Mvs $69M+2.2% |
| Q2 2026 | Mar 12, 2026 | $0.08vs $0.09-11.1% | $75Mvs $74M+1.0% |
| Q4 2025 | Nov 10, 2025 | $0.06vs $0.05+20.0% | $76Mvs $74M+3.0% |
| Q3 2025 | Aug 7, 2025 | $0.04vs $0.03+33.3% | $81Mvs $85M-5.2% |
Based on last 12 quarters of dataView full earnings history →
HCAT Peer Comparison
Health Catalyst, Inc. (HCAT) competitors in Healthcare Data, Analytics and AI — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 DOCS | 3.83B | 20.46 | 20.88 | 13.05% | 30.4% | 19.36% | 0.01 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 TDOC | 1.46B | 8.07 | -7.08 | -1.54% | -6.81% | -12.37% | 0.75 | |
 PINC | 2.34B | 28.26 | 128.45 | -10.86% | -2.42% | -1.59% | 0.18 | |
 MSFT | 2.82T | 379.40 | 27.82 | 14.93% | 39.34% | 33.13% | 0.33 | |
 ORCL | 530.08B | 184.31 | 31.61 | 17.35% | 25.37% | 49.81% | 3.63 | |
 CRM | 124.31B | 151.78 | 19.46 | 9.58% | 18.73% | 14.95% | 0.29 |
Compare HCAT vs Peers
Health Catalyst, Inc. (HCAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HCAT Income Statement
Health Catalyst, Inc. (HCAT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 73.08M | 112.57M | 154.94M | 188.84M | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M | 302.48M |
Revenue Growth % | - | 54.04% | 37.63% | 21.88% | 28.11% | 14.18% | 7.13% | 3.6% | 1.48% | -2.83% |
Cost of Goods Sold | 43.64M | 59.85M | 75.34M | 98.08M | 124.35M | 143.05M | 164.1M | 165.81M | 207M | 163.38M |
COGS % of Revenue | 59.72% | 53.17% | 48.63% | 51.94% | 51.4% | 51.79% | 55.45% | 54.08% | 66.53% | - |
Gross Profit | 29.44M▲ 0% | 52.72M▲ 79.1% | 79.6M▲ 51.0% | 90.77M▲ 14.0% | 117.57M▲ 29.5% | 133.19M▲ 13.3% | 131.83M▼ 1.0% | 140.78M▲ 6.8% | 104.13M▼ 26.0% | 139.1M▲ 0% |
Gross Margin % | 40.28% | 46.83% | 51.37% | 48.06% | 48.6% | 48.21% | 44.55% | 45.92% | 33.47% | 45.99% |
Gross Profit Growth % | - | 79.09% | 50.97% | 14.04% | 29.53% | 13.28% | -1.02% | 6.79% | -26.03% | - |
Operating Expenses | 74.98M | 112.82M | 134.46M | 186.89M | 261.22M | 273.19M | 258.73M | 210.59M | 140.24M | 197.19M |
OpEx % of Revenue | 102.6% | 100.22% | 86.78% | 98.97% | 107.98% | 98.9% | 87.43% | 68.69% | 45.07% | - |
Selling, General & Admin | 40.62M | 66.81M | 79M | 114.65M | 160.96M | 149.22M | 143.88M | 111.2M | 102.04M | 89.79M |
SG&A % of Revenue | 55.58% | 59.35% | 50.99% | 60.71% | 66.53% | 54.02% | 48.62% | 36.27% | 32.79% | - |
Research & Development | 28.47M | 38.59M | 46.25M | 53.52M | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M | 44.26M |
R&D % of Revenue | 38.96% | 34.28% | 29.85% | 28.34% | 25.93% | 27.4% | 24.54% | 18.9% | 16% | - |
Other Operating Expenses | -4K | -39K | 9.21M | 18.73M | 37.53M | 48.3M | 42.22M | 41.43M | -11.57M | 2M |
Operating Income | -45.54M▲ 0% | -60.09M▼ 32.0% | -54.87M▲ 8.7% | -96.13M▼ 75.2% | -143.65M▼ 49.4% | -140M▲ 2.5% | -126.9M▲ 9.4% | -69.81M▲ 45.0% | -36.1M▲ 48.3% | -58.09M▲ 0% |
Operating Margin % | -62.31% | -53.38% | -35.41% | -50.9% | -59.38% | -50.68% | -42.88% | -22.77% | -11.6% | -19.2% |
Operating Income Growth % | - | -31.96% | 8.7% | -75.2% | -49.44% | 2.54% | 9.36% | 44.99% | 48.28% | - |
EBITDA | -39.65M | -52.68M | -45.65M | -77.4M | -102.54M | -88.48M | -84.67M | -28.38M | 14.4M | -7.79M |
EBITDA Margin % | -54.25% | -46.8% | -29.46% | -40.99% | -42.38% | -32.03% | -28.61% | -9.26% | 4.63% | -2.58% |
EBITDA Growth % | - | -32.88% | 13.34% | -69.54% | -32.48% | 13.71% | 4.3% | 66.49% | 150.73% | 67.44% |
D&A (Non-Cash Add-back) | 5.89M | 7.41M | 9.21M | 18.73M | 41.11M | 51.53M | 42.22M | 41.43M | 50.5M | 50.3M |
EBIT | -45.54M | -60.09M | -56.53M | -104.64M | -142.79M | -134.44M | -110.5M | -52.08M | -36.1M | -143.54M |
Net Interest Income | -1.47M | -1.99M | -3.45M | -11.62M | -16.48M | -1.55M | 9.1M | 896K | -8.87M | -17.18M |
Interest Income | 542K | 602K | 2.81M | 2.09M | 831K | 5.69M | 16.39M | 17.98M | 7.54M | 4.5M |
Interest Expense | 2.01M | 2.59M | 6.26M | 13.72M | 17.31M | 7.24M | 7.29M | 17.09M | 16.4M | 21.68M |
Other Income/Expense | -1.47M | -2.02M | -5.09M | -20.09M | -16.46M | -1.68M | 9.11M | 637K | -141.15M | -206.25M |
Pretax Income | -47.01M▲ 0% | -62.12M▼ 32.1% | -59.95M▲ 3.5% | -116.21M▼ 93.8% | -160.11M▼ 37.8% | -141.68M▲ 11.5% | -117.79M▲ 16.9% | -69.17M▲ 41.3% | -177.26M▼ 156.3% | -264.34M▲ 0% |
Pretax Margin % | -64.32% | -55.18% | -38.69% | -61.54% | -66.18% | -51.29% | -39.8% | -22.56% | -56.97% | -87.39% |
Income Tax | 26K | -135K | 142K | -1.19M | -6.9M | -4.28M | 356K | 333K | 716K | 915K |
Effective Tax Rate % | -0.06% | 0.22% | -0.24% | 1.03% | 4.31% | 3.02% | -0.3% | -0.48% | -0.4% | -0.35% |
Net Income | -47.03M▲ 0% | -61.98M▼ 31.8% | -60.1M▲ 3.0% | -115.02M▼ 91.4% | -153.21M▼ 33.2% | -137.4M▲ 10.3% | -118.15M▲ 14.0% | -69.5M▲ 41.2% | -177.97M▼ 156.1% | -265.26M▲ 0% |
Net Margin % | -64.36% | -55.06% | -38.79% | -60.91% | -63.33% | -49.74% | -39.92% | -22.67% | -57.2% | -87.69% |
Net Income Growth % | - | -31.78% | 3.05% | -91.39% | -33.21% | 10.32% | 14.01% | 41.17% | -156.07% | -265.08% |
Net Income (Continuing) | -47.03M | -61.98M | -60.1M | -115.02M | -153.21M | -137.4M | -118.15M | -69.5M | -177.97M | -265.26M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.69▲ 0% | -2.23▼ 32.0% | -3.21▼ 43.9% | -2.91▲ 9.3% | -3.23▼ 11.0% | -2.54▲ 21.4% | -2.09▲ 17.7% | -1.15▲ 45.0% | -2.55▼ 121.7% | -3.65▲ 0% |
EPS Growth % | - | -31.95% | -43.95% | 9.35% | -11% | 21.36% | 17.72% | 44.98% | -121.74% | -223.48% |
EPS (Basic) | -1.69 | -2.23 | -3.21 | -2.91 | -3.23 | -2.56 | -2.09 | -1.15 | -2.55 | - |
Diluted Shares Outstanding | 27.77M | 27.77M | 18.74M | 39.54M | 47.49M | 54.08M | 56.42M | 60.19M | 69.9M | 72.59M |
Basic Shares Outstanding | 27.77M | 27.77M | 18.74M | 39.54M | 47.49M | 53.72M | 56.42M | 60.19M | 69.9M | 72.59M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HCAT Balance Sheet
Health Catalyst, Inc. (HCAT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 71.39M | 66.86M | 264.24M | 329.8M | 508.39M | 427.8M | 393.4M | 465.65M | 169.31M | 182.31M |
Cash & Short-Term Investments | 51.46M | 33.19M | 228.28M | 270.87M | 444.98M | 363.49M | 317.73M | 392M | 95.73M | 108.82M |
Cash Only | 22.98M | 28.43M | 18.03M | 91.95M | 193.23M | 116.31M | 106.28M | 249.65M | 50.81M | 59.86M |
Short-Term Investments | 28.48M | 4.76M | 210.25M | 178.92M | 251.75M | 247.18M | 211.45M | 142.35M | 44.92M | 48.96M |
Accounts Receivable | 17.05M | 27.7M | 27.57M | 48.3M | 48.8M | 47.97M | 60.29M | 57.18M | 59.13M | 59.15M |
Days Sales Outstanding | 85.17 | 89.8 | 64.95 | 93.35 | 73.63 | 63.38 | 74.36 | 68.08 | 69.36 | 74.44 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 762K | 649K | 0 | 0 | 14.61M | 16.34M | 15.38M | 16.47M | 14.45M | 14.34M |
Total Non-Current Assets | 38.88M | 44.12M | 38.12M | 247.94M | 323.7M | 324.49M | 308.42M | 393.28M | 333.34M | 229.89M |
Property, Plant & Equipment | 5.38M | 11.02M | 8.08M | 37.59M | 44.45M | 42.59M | 39.64M | 41.45M | 40.48M | 41.19M |
Fixed Asset Turnover | 13.58x | 10.22x | 19.17x | 5.02x | 5.44x | 6.49x | 7.47x | 7.40x | 7.69x | 7.23x |
Goodwill | 3.69M | 3.69M | 3.69M | 107.82M | 169.97M | 185.98M | 190.65M | 259.76M | 209.07M | 113.25M |
Intangible Assets | 29.57M | 28.3M | 25.54M | 98.92M | 104.79M | 92.19M | 73.38M | 86.05M | 77.68M | 69.33M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 243K | 1.1M | 810K | 3.61M | 4.5M | 3.73M | 4.74M | 6.02M | 6.11M | 6.12M |
Total Assets | 110.27M▲ 0% | 110.97M▲ 0.6% | 302.36M▲ 172.5% | 577.74M▲ 91.1% | 832.1M▲ 44.0% | 752.29M▼ 9.6% | 701.81M▼ 6.7% | 858.93M▲ 22.4% | 502.64M▼ 41.5% | 412.2M▲ 0% |
Asset Turnover | 0.66x | 1.01x | 0.51x | 0.33x | 0.29x | 0.37x | 0.42x | 0.36x | 0.62x | 0.57x |
Asset Growth % | - | 0.64% | 172.46% | 91.08% | 44.03% | -9.59% | -6.71% | 22.39% | -41.48% | -133.95% |
Total Current Liabilities | 30.77M | 41.81M | 48.22M | 88.04M | 93.05M | 82.51M | 89.03M | 325.85M | 89.57M | 107.61M |
Accounts Payable | 833K | 1.81M | 3.62M | 5.33M | 4.69M | 4.42M | 6.64M | 11.43M | 9.36M | 11.69M |
Days Payables Outstanding | 6.97 | 11.05 | 17.55 | 19.84 | 13.77 | 11.29 | 14.77 | 25.17 | 16.51 | 19.51 |
Short-Term Debt | 0 | 1.29M | 2.81M | 0 | 0 | 0 | 0 | 231.18M | 5.41M | 5.36M |
Deferred Revenue (Current) | 10.72M | 24.75M | 30.65M | 47.15M | 56.63M | 54.96M | 55.75M | 53.28M | 56.11M | 251.68M |
Other Current Liabilities | 16.27M | 5.49M | 4.05M | 24.27M | 10.87M | 7.51M | 11.68M | 11.65M | 18.7M | 20.82M |
Current Ratio | 2.32x | 1.60x | 5.48x | 3.75x | 5.46x | 5.18x | 4.42x | 1.43x | 1.89x | 1.69x |
Quick Ratio | 2.32x | 1.60x | 5.48x | 3.75x | 5.46x | 5.18x | 4.42x | 1.43x | 1.89x | 1.69x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 54.93 |
Total Non-Current Liabilities | 338.98M | 443.94M | 53.5M | 213.6M | 216.95M | 244.77M | 245.86M | 167.87M | 167.29M | 166.44M |
Long-Term Debt | 9.62M | 18.81M | 48.2M | 168.99M | 180.94M | 226.52M | 228.03M | 151.18M | 151.62M | 13.48M |
Capital Lease Obligations | 872K | 4.23M | 1.65M | 23.67M | 20.24M | 18.02M | 17.68M | 16.29M | 14.21M | 45.22M |
Deferred Tax Liabilities | 0 | -4.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 328.49M | 413.62M | 2.19M | 19.06M | 14.83M | 121K | 74K | 154K | 798K | 152.96M |
Total Liabilities | 369.74M | 485.74M | 101.72M | 301.64M | 310M | 327.28M | 334.89M | 493.72M | 256.86M | 274.06M |
Total Debt | 12.62M | 26.91M | 52.66M | 195.28M | 204.61M | 247.97M | 249.07M | 402.26M | 171.24M | 18.84M |
Net Debt | -10.35M | -1.52M | 34.63M | 103.33M | 11.38M | 131.66M | 142.79M | 152.62M | 120.42M | -41.02M |
Debt / Equity | - | - | 0.26x | 0.71x | 0.39x | 0.58x | 0.68x | 1.10x | 0.70x | 0.14x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 11.89x | -2.42x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 8.37x | 5.26x |
Interest Coverage | -22.69x | -23.23x | -9.03x | -7.63x | -8.25x | -18.57x | -15.16x | -3.05x | -2.20x | -6.62x |
Total Equity | -259.48M▲ 0% | -374.77M▼ 44.4% | 200.64M▲ 153.5% | 276.1M▲ 37.6% | 522.1M▲ 89.1% | 425.01M▼ 18.6% | 366.92M▼ 13.7% | 365.21M▼ 0.5% | 245.78M▼ 32.7% | 138.15M▲ 0% |
Equity Growth % | - | -44.43% | 153.54% | 37.61% | 89.1% | -18.6% | -13.67% | -0.47% | -32.7% | -105.2% |
Book Value per Share | -9.34 | -13.50 | 10.71 | 6.98 | 10.99 | 7.86 | 6.50 | 6.07 | 3.52 | 1.90 |
Total Shareholders' Equity | -259.48M | -374.77M | 200.64M | 276.1M | 522.1M | 425.01M | 366.92M | 365.21M | 245.78M | 138.15M |
Common Stock | 5K | 5K | 37K | 43K | 53K | 1.42B | 1.48B | 1.55B | 1.61B | 1.61B |
Retained Earnings | -259.47M | -374.77M | -610.51M | -725.65M | -878.86M | -999.02M | -1.12B | -1.19B | -1.36B | -1.48B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -12K | -1K | 72K | 61K | -67K | -648K | 33K | -835K | 1.59M | 1.01M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HCAT Cash Flow Statement
Health Catalyst, Inc. (HCAT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -36.83M | -40.3M | -32.18M | -26.15M | -23.12M | -35.27M | -33.08M | 14.56M | 731K | 18.96M |
Operating CF Margin % | -50.39% | -35.8% | -20.77% | -13.85% | -9.56% | -12.77% | -11.18% | 4.75% | 0.23% | - |
Operating CF Growth % | - | -9.41% | 20.13% | 18.75% | 11.57% | -52.53% | 6.21% | 144.01% | -94.98% | 6126.5% |
Net Income | -47.03M | -61.98M | -60.1M | -115.02M | -153.21M | -137.4M | -118.15M | -69.5M | -177.97M | -265.26M |
Depreciation & Amortization | 5.89M | 7.41M | 9.21M | 18.73M | 37.53M | 48.3M | 42.22M | 41.43M | 50.5M | 50.3M |
Stock-Based Compensation | 4.24M | 4.2M | 17.84M | 37.96M | 65.14M | 72.1M | 55.76M | 40.13M | 27.01M | 19.47M |
Deferred Taxes | 14K | -206K | 40K | -1.27M | -7.13M | -4.52M | 8K | 77K | 81K | 58K |
Other Non-Cash Items | 225K | 533K | 2.08M | 37.29M | 29.93M | 162K | 750K | 3.08M | 116.22M | 215.76M |
Working Capital Changes | -166K | 9.75M | -1.27M | -3.83M | 4.62M | -13.91M | -13.67M | -660K | -15.11M | -1.36M |
Change in Receivables | 4.44M | -3.63M | 127K | -16.45M | 102K | 788K | -13.66M | 4.28M | -1.81M | 3.67M |
Change in Inventory | -2.56M | 2.46M | -3.65M | 0 | -8.32M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -6.29M | 4.42M | -86K | 8.24M | 5.2M | -4.7M | 4.87M | 5.58M | -11.51M | 91K |
Cash from Investing | 22.41M | 21.4M | -209.6M | -82.56M | -139.68M | -39.02M | 20.29M | -22.9M | 36.19M | -69.97M |
Capital Expenditures | -3.34M | -2.5M | -4.33M | -10.46M | -18.47M | -2.17M | -1.24M | -1.62M | -968K | -10.67M |
CapEx % of Revenue | 4.58% | 2.22% | 2.8% | 5.54% | 7.63% | 0.78% | 0.42% | 0.53% | 0.31% | 3.53% |
Acquisitions | 878K | 228K | 1.94M | -101.66M | -46.76M | -27.85M | -11.39M | -80.28M | -41.11M | 18K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -831K | -199K | -1.87M | 14K | 22K | -15.22M | -13.04M | -14.77M | -20.54M | -11.01M |
Cash from Financing | 24.87M | 24.35M | 231.38M | 182.61M | 264.08M | -2.61M | 2.73M | 151.75M | -235.78M | -231.07M |
Debt Issued (Net) | 9.79M | 9.95M | 25.35M | 165.44M | 0 | 0 | 0 | 151.32M | -232.29M | -232.29M |
Equity Issued (Net) | 0 | -8.71M | 206.72M | 40.54M | 245.18M | -8.39M | -1.81M | 2.58M | -3.49M | 1.22M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -8.71M | 0 | 0 | 0 | -8.39M | -1.81M | 0 | -5M | 0 |
Other Financing | 15.08M | 23.11M | -689K | -23.37M | 18.9M | 5.78M | 4.54M | -2.15M | 0 | 0 |
Net Change in Cash | 10.45M▲ 0% | 5.45M▼ 47.8% | -10.4M▼ 290.7% | 73.92M▲ 810.9% | 101.27M▲ 37.0% | -76.92M▼ 175.9% | -10.04M▲ 87.0% | 143.37M▲ 1528.5% | -198.83M▼ 238.7% | -282.1M▲ 0% |
Free Cash Flow | -40.17M▲ 0% | -42.8M▼ 6.5% | -36.52M▲ 14.7% | -36.61M▼ 0.3% | -41.59M▼ 13.6% | -52.68M▼ 26.7% | -47.39M▲ 10.0% | -1.84M▲ 96.1% | -237K▲ 87.1% | 9.17M▲ 0% |
FCF Margin % | -54.97% | -38.02% | -23.57% | -19.39% | -17.19% | -19.07% | -16.01% | -0.6% | -0.08% | 3.03% |
FCF Growth % | - | -6.54% | 14.68% | -0.26% | -13.59% | -26.67% | 10.05% | 96.12% | 87.11% | 194.8% |
FCF per Share | -1.45 | -1.54 | -1.95 | -0.93 | -0.88 | -0.97 | -0.84 | -0.03 | -0.00 | 0.13 |
FCF Conversion (FCF/Net Income) | 0.78x | 0.65x | 0.54x | 0.23x | 0.15x | 0.26x | 0.28x | -0.21x | -0.00x | -0.03x |
Interest Paid | 1.03M | 3.94M | 5.56M | 4.98M | 6.36M | 5.75M | 5.75M | 10.12M | 0 | 0 |
Taxes Paid | 66K | 31K | 19K | 92K | 138K | 297K | 266K | 10.12M | 0 | 0 |
HCAT Key Ratios
Health Catalyst, Inc. (HCAT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -29.95% | -48.25% | -38.39% | -29.02% | -29.84% | -18.99% | -58.26% | -99.78% |
Return on Invested Capital (ROIC) | - | -17.49% | -23.46% | -23.6% | -19.26% | -17.85% | -10.19% | -6.13% | -12.48% |
Gross Margin | 46.83% | 51.37% | 48.06% | 48.6% | 48.21% | 44.55% | 45.92% | 33.47% | 45.99% |
Net Margin | -55.06% | -38.79% | -60.91% | -63.33% | -49.74% | -39.92% | -22.67% | -57.2% | -87.69% |
Debt / Equity | - | 0.26x | 0.71x | 0.39x | 0.58x | 0.68x | 1.10x | 0.70x | 0.14x |
Interest Coverage | -23.23x | -9.03x | -7.63x | -8.25x | -18.57x | -15.16x | -3.05x | -2.20x | -6.62x |
FCF Conversion | 0.65x | 0.54x | 0.23x | 0.15x | 0.26x | 0.28x | -0.21x | -0.00x | -0.03x |
Revenue Growth | 54.04% | 37.63% | 21.88% | 28.11% | 14.18% | 7.13% | 3.6% | 1.48% | -2.83% |
Related:HCAT Dividend History·HCAT Revenue History·HCAT Price History·HCAT P/E History·HCAT Financial Ratios·HCAT Institutional Holders
HCAT SEC Filings & Documents
Health Catalyst, Inc. (HCAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
HCAT Frequently Asked Questions
Health Catalyst, Inc. (HCAT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Health Catalyst, Inc. (HCAT) reported $302.5M in revenue for fiscal year 2025. This represents a 314% increase from $73.1M in 2017.
Health Catalyst, Inc. (HCAT) grew revenue by 1.5% over the past year. Growth has been modest.
Health Catalyst, Inc. (HCAT) reported a net loss of $265.3M for fiscal year 2025.
Dividend & Returns
Health Catalyst, Inc. (HCAT) has a return on equity (ROE) of -58.3%. Negative ROE indicates the company is unprofitable.
Health Catalyst, Inc. (HCAT) generated $9.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.